Medicare and Amyloid PET Imaging: The Battle Over Evidence

Area of Science:

• Medical policy
• Health economics
• Neurology

Background:

• The Centers for Medicare and Medicaid Services (CMS) has specific coverage criteria for amyloid positron emission tomography (PET) imaging.
• Alzheimer's disease diagnosis often involves advanced imaging techniques like amyloid PET scans.

Purpose of the Study:

• To analyze the dispute surrounding CMS's coverage policy for amyloid PET imaging.
• To examine the differing evidentiary standards used by CMS and the Food and Drug Administration (FDA).

Main Methods:

• Policy analysis of CMS coverage decisions.
• Review of stakeholder perspectives on evidentiary requirements.

Main Results:

• CMS mandates enrollment in specific clinical trials for amyloid PET scan reimbursement.
• This policy reflects a divergence from the FDA's pre-market approval standards for medical interventions.
• Stakeholder input influences Medicare coverage policies.

Conclusions:

• CMS's coverage decisions for amyloid PET imaging demonstrate a unique approach to evidence requirements.
• The case illustrates the impact of varied stakeholder viewpoints on Medicare's evolving coverage landscape.